MedTrace Logo

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

NCT01222351 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2024-05-06

Study results available
· View outcomes & findings →

Summary

The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline. The investigators will use baseline and longitudinal measurements of plasma amyloid beta-40 and amyloid beta-42 to investigate the risk of developing mild cognitive impairment and late onset Alzheimer's disease, as well as the rates of cognitive decline and Alzheimer's disease progression. The driving hypothesis of the study is that amyloid beta in the brain as measured by positron emission tomography positivity is associated with the onset of cognitive decline associated with late onset Alzheimer's disease.

Conditions

  • Late Onset Alzheimer Disease

Interventions

DRUG

BAY 94-9172 (Florbetaben)

Measure of brain amyloid load using BAY 94-9172 PET/CT

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • National Institute on Aging (NIA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Richard Mayeux, BS, MD, MSc · Columbia University

  • Yaakov Stern, BA, PhD · Columbia University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2014-10-22
Completion
2014-10-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222351 on ClinicalTrials.gov